New investment will enhance immunochemistry and chromatography services, helping pharma and biotech customers accelerate drug development
March 14, 2022 08:36 AM Eastern Daylight Time
WILMINGTON, N.C.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced it will invest $97 million to expand its clinical research operations in Richmond, Virginia. The facilities, which include laboratory operations acquired with the purchase of PPD, Inc. in December 2021, will support increasing demand across biopharma for consistent, high-quality laboratory services to accelerate drug development.
Over the next three years, Thermo Fisher expects to add nearly 150,000 square feet and more than 500 new employees in Richmond. The existing laboratory services operation in Richmond comprises more than 300,000 square feet, making it one of the largest laboratories of its kind in the world, and it employs more than 1,200 professionals, including Ph.D.-level scientists, analytical laboratory staff and other scientific professionals. The bulk of the expansion will occur in immunochemistry and chromatography functions, as well as subsequent enhancements in biomarker and vaccine sciences.
Virginia Governor Glenn Youngkin said, “Thermo Fisher’s expanding footprint and creation of more than 500 new jobs is a major win for the Greater Richmond region and Virginia’s life sciences industry. This sector has gained significant momentum in the Commonwealth due to our research institutions, skilled talent and advanced innovation ecosystem, and we are proud of the company’s developments happening right here in Virginia.”
The Richmond bioanalytical lab, elements of which have been operating since 1985, provides services for all phases of biopharmaceutical development for small molecule drugs, biologics, vaccines and biomarker testing. Drug testing services include drug pharmacokinetics and pharmacodynamics (PK/PD), immunogenicity and biomarker quantitation to support drug efficacy and safety.
In addition to bioanalytical, biomarker and vaccine sciences labs in Richmond, Thermo Fisher’s clinical research business includes bioanalytical and good manufacturing practices (GMP) labs in Middleton, Wisconsin; a GMP lab in Athlone, Ireland; central labs in Shanghai, China, Brussels, Belgium, Highland Heights, Kentucky, and Singapore; a biomarker lab in Highland Heights; and a multipurpose bioanalytical, biomarker and vaccine sciences lab in Suzhou, China.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Contacts Media Contact Information: Randy Buckwalter Thermo Fisher Scientific Phone: 919-456-4425 E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.